DIAGENS-B

2526
104.50022.94% ( +19.500 )
Delay Closed: Nov 16, 16:08:11

Overview

DIAGENS-B (2526)

Hangzhou Diagens Biotechnology Co., Ltd., a medical devices company, develops medical imaging products and services. It operates through Medical Imaging Softwar...

Open
87.600
High
114.500
Low
86.000
Prev. Close
85.000
Volume
1.99M
Turnover
207.59M
Avg Price
104.278
Bid/Ask Ratio
-37.50%
Amplitude
33.53%
52wk High
765.500
Volume Ratio
30.89
Turnover Ratio
2.24%
52wk Low
82.000
HK Mkt Cap
9.29B
Market CapHKD
9.29B
P/ETTM
Loss
P/EDynamic
Loss
P/EStatic
--
EPSTTM
-1.58
EPSDynamic
-1.45
EPSStatic
--
BVPS
10.04
P/B
10.41
HK Shares
88.88M
Dividend YieldTTM
--
DividendTTM
--
Shares
88.88M
Min lot size
50
Currency
HKD

DIAGENS-B Analyst Rating

View more

Forecast & Rating

Nov 2, 2026
Price forecast
HK$296.17183.41%
Forecast & RatingStrong buy
1analysts
  • Strong buy100.00%
  • Buy0.00%
  • Hold0.00%
  • Sell0.00%
  • Strong sell0.00%

Daily Events

  1. Nov, 16

    Diagens-B (2526.HK) rebounded 22.9% to HK$104.5 versus a prior close of HK$85.0, opening at HK$87.6, dipping to HK$93.3 early before spiking to HK$114.5 at 15:26 and closing near the day's midpoint, on 1.97 million shares worth about HK$206 million; the triggers were progress on its iMed-6.0 medical-imaging models, disclosure that its chest-and-abdominal CT analysis now covers 509 imaging targets, and a medical-imaging AI partnership with the Guangxi laboratory. Fundamentals cut both ways: Q2 revenue rose 27.6% year on year to HK$62.8 million, yet the net loss widened to HK$32.3 million at a -51.4% net margin. The shares still trade below the MA20 of HK$146.56 and MA60 of HK$316.12, down 50.1% year to date and 86.4% below the HK$765.5 52-week high, though 27.4% above the HK$82.0 low, with PB at 10.41 against a PE of -66.3. Though the Hang Seng added only 0.84% at midday, the stock's intraday range exceeded 30%, pointing more to low-level positioning flows.

  2. Nov, 13

    Diagens-B (2526.HK) spiked and then faded to close at HK$85.00, down 8.6%, as the bounce off the prior session's 52-week low of HK$82.00 failed: the stock reached HK$94.45 in the morning session before sliding to HK$82.25 at 15:25 BJ, a drawdown of more than 13% from the intraday high. Q2 2026 revenue grew 27.58% year on year to HK$62.77 million, yet the net loss widened to HK$32.27 million with a -51.41% net margin and EPS of -HK$0.3798, leaving the shares at a PE of -53.93 and PB of 8.47. Disclosures on the iMed-6.0 imaging models, the extension of chest and abdominal CT analysis to 509 imaging targets and a partnership with Guangxi Laboratory did not reverse the drift. The stock is down 59.45% year to date, 88.9% below its 52-week high of HK$765.5, and trades well under its MA20 of 152.94 and MA60 of 321.4. Though it sits only 3.66% above the 52-week low, volume of 204,200 shares and a 0.23% turnover rate point to thin liquidity.

  3. Nov, 12

    Diagens-B reversed early losses but faded again in the afternoon, last at HK$93.00 against a HK$91.60 prior close, up 1.5%, after touching HK$86.00 at 09:37 BJ, rallying to HK$94.30 by 11:46 and then easing to roughly HK$90.50. The swing tracks a choppy news tape: the stock had just printed a fresh 52-week low, yet also logged single-day jumps of 14% and 10%, with the medical-imaging AI theme doing the work through a tie-up with the Guangxi laboratory on imaging AI and a state science award for a Chinese medical AI model. Fundamentals show revenue growth against widening losses: Q2 revenue HK$62.8m, up 27.58% year on year, with a net loss of HK$32.3m and a -51.41% net margin. The price remains far below its averages, down 55.63% year to date and 87.85% below the 52-week high of HK$765.50, versus MA20 of HK$159.57 and MA60 of HK$325.50. Though turnover of HK$30.8m and a 0.38% turnover rate point to thin participation.

  4. Nov, 11

    Diagens-B reversed intraday to close down 3.3% at HK$91.60, having spiked to HK$98.65 at 14:34 in the afternoon session before sliding to HK$90.50 by 15:12, an intraday range of more than 8% on HK$37.4 million turnover and a thin 0.45% turnover rate. The medical-imaging AI tie-up with the Guangxi laboratory and a single-day jump of more than 10% both failed to hold, with last week's 29.18% slide and a fresh test of the 52-week low at HK$89.80 leaving the rebound unfinished. Q2 revenue rose 27.58% year on year to HK$62.77 million, yet the net loss stayed at HK$32.27 million with a -51.41% net margin and a HK$0.3798 per-share loss; the stock trades at -58.11x PE and 9.12x PB. At HK$91.60 it sits 88.03% below the HK$765.50 52-week high, down 56.30% year to date, and well under MA20 of HK$165.89 and MA60 of HK$330.06. Though a grant of 778,962 share awards to 23 employees remains in progress.

  5. Nov, 10

    A strategic cooperation pact with Yongjiang Laboratory to demonstrate large medical imaging models in Guangxi failed to hold the stock up, and the shares gapped to HK$105.00 before reversing to close at HK$95.00, down 4.95%, with an afternoon slide to HK$90.35 at 14:10 BJ and an intraday range above 15%. The move extends a weak stretch in which the stock fell roughly 29% over the prior week and printed a 52-week low of HK$89.80. Fundamentals cut both ways: Q2 revenue rose 27.58% year on year to HK$62.77 million, yet the net loss reached HK$32.27 million on a -51.41% net margin, against a 9.46x price-to-book. The price sits 54.68% lower year to date, 87.59% below the 52-week high of HK$765.50 and well under its MA20 of 172.72 and MA60 of 334.78; Huatai Securities initiated coverage with a HK$296.13 target, though spot remains far from that level.

News